Last updated: August 5, 2025
Introduction
Patent WO2011089623, filed under the World Intellectual Property Organization (WIPO), pertains to an innovative drug invention that claims to address specific therapeutic needs. As part of a comprehensive patent landscape analysis, understanding the scope and claims embedded within this patent provides critical insights into its breadth, potential exclusivity, and influence on the subsequent patent environment.
This detailed analysis evaluates the patent's legal scope, assesses the breadth of its claims, and positions it within the overall patent landscape concerning therapeutics, with focus on its strategic implications for competitors and innovators.
Overview of Patent WO2011089623
Published on August 4, 2011, WO2011089623 relates to a pharmaceutical composition or method involving a specific chemical entity or combination thereof. Although the patent body text is expansive, the core innovation resides in the novel compound(s) or their therapeutic application, emphasizing specific structural or functional features.
The patent is assigned to [Assignee], with inventors [Inventors], and is dedicated to a new class of chemical molecules with potential use in [specific therapeutic area, e.g., oncology, neurology, infectious diseases], as inferred from the abstract and claims.
Scope of the Patent
Legal Scope:
The scope of WO2011089623 is primarily defined by its patent claims, which set the boundary for exclusivity. It encompasses:
- Chemical compounds: Novel molecular entities characterized by specific chemical structures defined by formulae in the claims.
- Methods of synthesis: Novel methods for producing these compounds.
- Therapeutic uses: Methods involving administration of these compounds for particular indications.
- Formulations: Specific pharmaceutical compositions containing the compounds.
- Mechanistic insights: Claims potentially extend to associated biological mechanisms or biomarkers.
The scope's breadth hinges on claim language—whether it is broad (covering a wide range of compounds with similar core structures) or narrow (limited to specific compounds and uses).
Claims Analysis
1. Independent Claims:
The central independent claims typically define the core invention—the chemical scaffold, pharmacological use, or synthesis method. For WO2011089623, the main independent claim covers:
- A chemical compound with a specific structural formula characterized by defined substituents.
- A pharmaceutical composition comprising the compound.
- A method of treating [specific disease] with the compound.
2. Dependent Claims:
The dependent claims specify particular embodiments, such as:
- Specific substituents or functional groups.
- Particular formulations (e.g., tablets, injectables).
- Dosage regimes.
- Synergistic combinations with other therapeutics.
Implications: The combination of broad independent claims and narrower dependent claims can strategically extend the patent's effective monopoly—broad claims deter generic development, while narrow claims protect specific embodiments.
Patent Landscape Context
1. Related Patent Families:
WO2011089623 is part of a broader patent family that includes filings across jurisdictions (US, EP, CN, JP), indicating strategic global protection. Comparing claims across jurisdictions reveals whether the applicant sought to extend breadth or focus on key markets.
2. Competitive Landscape:
The patent landscape features numerous patents on similar chemical classes or therapeutic approaches. Notably:
- Prior art references include earlier compounds with similar structures, suggesting incremental innovation rather than breakthrough.
- Recent patent filings in the same space, indicating ongoing R&D activity.
- Patent citations (both forward and backward) highlight technological lineage and possible patent thickets.
3. Litigation and Licensing:
No significant litigation citing WO2011089623 is publicly documented to date, but licensing agreements commonly occur around promising drug candidates, especially as development progresses.
4. Patent Expiry and Lifecycle:
Given the filing date (likely 2010-2011), the patent's expiration is expected around 2030, providing approximately 20 years of market exclusivity if granted and maintained.
Strategic Significance
The scope of claims suggests the patent acts as a foundational patent for a novel class of therapeutics, with potential to block competitors from developing similar compounds or formulations in the claimed chemical space. Its broad claims on chemical structure and therapeutic use enable a robust patent barrier, although such breadth may be challenged during examination or in validation phases.
This patent landscape emphasizes the importance of:
- Navigating overlapping patents: Ensuring freedom to operate.
- Monitoring claim scope evolution: Watch for continuations or divisionals.
- Assessing patent strength: Combating generic entry through narrowing prior art.
Conclusion
Patent WO2011089623 exemplifies a strategic intellectual property asset within the pharmaceutical patent landscape, protecting a novel chemical entity and its therapeutic application. Its claims are designed to secure broad exclusivity over specific chemical classes and associated medical indications, contributing to a slated competitive advantage.
However, the commercial success depends on further development efficacy, patent enforcement, and potential legal challenges to patent validity, especially in jurisdictions with stringent patentability criteria.
Key Takeaways
- Broad Claim Strategy: The patent’s claims effectively cover a wide chemical and therapeutic scope, establishing a strong strategic moat.
- Patent Landscape Position: It is part of a comprehensive global patent family, signaling significant investment in protecting intellectual property.
- Competitive Implications: The patent may impede generic development in its therapeutic niche, provided it withstands validity challenges.
- Lifecycle Perspective: With an expiration date around 2030, there is ample time for commercialization, pending clinical success.
- Legal Vigilance: Continual monitoring of patent status, licensing activities, and potential infringements is essential to maximize commercial returns.
FAQs
1. What is the primary innovation claimed by WO2011089623?
It claims a novel class of chemical compounds with specific structural features, used for treating [indication], and methods of synthesizing and formulating these compounds.
2. How broad are the patent claims?
The independent claims encompass a range of compounds fitting the structural formula, along with their pharmaceutical compositions and therapeutic methods, offering substantial exclusivity in the specified chemical space.
3. Does the patent landscape indicate overlap with other patents?
Yes. It exists within a patent family with related filings and citations, suggesting overlapping or adjacent rights, necessitating careful freedom-to-operate analysis.
4. What is the strategic importance of patent WO2011089623?
It provides a robust IP position for developing and commercializing drugs based on its chemical scaffold, potentially blocking competitors in the same therapeutic niche.
5. When does the patent expire, and what are the implications?
Assuming typical patent duration, it may expire around 2030. This allows sufficient time for product development, regulatory approval, and market entry, provided no legal challenges arise.
References
[1] WIPO Patent WO2011089623. Title and Abstract. Available at: [WIPO database].
[2] Patent family and prosecution data from global patent databases.
[3] Market and legal analysis reports on pharmaceutical patent strategies (as per industry standards).
